novartis_rm_logo_pos_rgb.png

Euro Visions & Decisions on the Management of Retinal Diseases with Beovu® (brolucizumab)

Friday 2nd September 2022
17:00 (BST) - 19:30 (BST)
18:00 (CET) - 20:30 (CET)

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Ltd. and is for UK healthcare professionals only.

UK | August 2022 | 230205

Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms. To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners

Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.uk/yellowcard (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.report.novartis.com

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com

Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) and visual impairment due to diabetic macular oedema (DMO)